MODTX Stock Overview
A biotechnology company, develops a treatment for sepsis and septic shock in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Modus Therapeutics Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.28 |
| 52 Week High | SEK 2.89 |
| 52 Week Low | SEK 0.88 |
| Beta | 0.63 |
| 11 Month Change | -9.54% |
| 3 Month Change | -16.61% |
| 1 Year Change | -27.48% |
| 33 Year Change | -70.20% |
| 5 Year Change | n/a |
| Change since IPO | -75.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| MODTX | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0% | 5.0% | 1.4% |
| 1Y | -27.5% | 11.4% | 12.2% |
Return vs Industry: MODTX underperformed the Swedish Biotechs industry which returned 11.4% over the past year.
Return vs Market: MODTX underperformed the Swedish Market which returned 12.2% over the past year.
Price Volatility
| MODTX volatility | |
|---|---|
| MODTX Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: MODTX's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: MODTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 2 | John Öhd | www.modustx.com |
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide to treat patients with sepsis, septic shock, and severe malaria conditions, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Modus Therapeutics Holding AB (publ) Fundamentals Summary
| MODTX fundamental statistics | |
|---|---|
| Market cap | SEK 46.00m |
| Earnings (TTM) | -SEK 14.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs MODTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MODTX income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 14.90m |
| Earnings | -SEK 14.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 20, 2025
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MODTX perform over the long term?
See historical performance and comparison